Literature DB >> 11451038

Assessment of tear concentrations on therapeutic drug monitoring. II. Pharmacokinetic analysis of valproic acid in guinea pig serum, cerebrospinal fluid, and tears.

S Sato1, S Kitagawa, M Nakajima, K Shimada, A Honda, H Miyazaki.   

Abstract

PURPOSE: To quantitatively describe the pharmacokinetics of valproic acid (VPA) in guinea pig serum (total [Cf+b] and free [Cf]), cerebrospinal fluid (CSF) [C]CSF and tears [C]T using a simple kinetic model, and to examine whether [Cf] and [C]CSF can be predicted by [C]T using the resulting pharmacokinetic parameters.
METHODS: [Cf+b], [Cf], [C]CSF and [C]T were determined after bolus i.v. injection of 10 or 20 mg/kg VPA using GC/ECNCI/MS.
RESULTS: [Cf+b] could be quantitatively described by a two compartment model with linear elimination kinetics. [Cf] was separately analyzed using multi-exponential equations. [C]CSF was analyzed using a simple kinetic model in which the CSF compartment is independently connected with the serum compartment by the apparent diffusion constants (KINCSF and KOUTCSF). [C]T was analyzed using the same simple kinetic model used for [C]CSF. The values of [C]CSF and [Cf] in the steady state can be represented by the following equations; [C]CSF = KINCSF/KOUTCSF x [Cf], [Cf] = KOUT/KINT x [C]T, and indicating that [Cf] and [C]CSF can be predicted by [C]T using the resulting pharmacokinetic parameters.
CONCLUSIONS: The measurement of [C]T which can be collected non-invasively and estimated the pharmacokinetic parameters for [Cf], [C]CSF, and [C]T might be a very useful method for TDM of VPA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11451038     DOI: 10.1023/a:1011010528642

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

1.  Limits on optimizing ocular drug delivery.

Authors:  J C Keister; E R Cooper; P J Missel; J C Lang; D F Hager
Journal:  J Pharm Sci       Date:  1991-01       Impact factor: 3.534

Review 2.  Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations.

Authors:  V Baeyens; R Gurny
Journal:  Pharm Acta Helv       Date:  1997-09

3.  Distribution of valproate across the interface between blood and cerebrospinal fluid.

Authors:  H H Frey; W Löscher
Journal:  Neuropharmacology       Date:  1978-08       Impact factor: 5.250

4.  Secretion of drugs in tears.

Authors:  N J van Haeringen
Journal:  Curr Eye Res       Date:  1985-04       Impact factor: 2.424

5.  Lacrimal gland electrolyte and water secretion in the rabbit: localization and role of (Na+ + K+)-activated ATPase.

Authors:  D A Dartt; M Møller; J H Poulsen
Journal:  J Physiol       Date:  1981-12       Impact factor: 5.182

6.  Low and variable presence of valproic acid in human brain.

Authors:  D D Shen; G A Ojemann; R L Rapport; R L Dills; P N Friel; R H Levy
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

7.  Assessment of valproic acid serum-cerebrospinal fluid transport by microdialysis.

Authors:  P L Golden; K R Brouwer; G M Pollack
Journal:  Pharm Res       Date:  1993-12       Impact factor: 4.200

8.  Blood-brain barrier transport of valproic acid.

Authors:  E M Cornford; C P Diep; W M Pardridge
Journal:  J Neurochem       Date:  1985-05       Impact factor: 5.372

9.  Protein binding of chlorpromazine in vivo and in vitro: effect of chlorpromazine metabolite on chlorpromazine protein binding in rat.

Authors:  S Sato; A Koshiro
Journal:  Biol Pharm Bull       Date:  1995-04       Impact factor: 2.233

10.  Pharmacokinetic analysis of chlorpromazine in rat serum, cerebrospinal fluid and striatum.

Authors:  S Sato; A Koshiro
Journal:  Biol Pharm Bull       Date:  1995-04       Impact factor: 2.233

View more
  1 in total

1.  Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers.

Authors:  M Valle; M J Barbanoj; A Donner; I Izquierdo; U Herranz; N Klein; H G Eichler; M Müller; M Brunner
Journal:  Eur J Clin Pharmacol       Date:  2005-02-12       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.